Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcturus Therapeutics Ltd.

14.19
+0.24001.72%
Volume:98.49K
Turnover:1.38M
Market Cap:384.84M
PE:-5.62
High:14.24
Open:13.75
Low:13.74
Close:13.95
Loading ...

BTIG Initiates Arcturus Therapeutics Holdings at Buy With $41 Price Target

MT Newswires Live
·
28 Jan

Arcturus Therapeutics initiated with a Buy at BTIG

TIPRANKS
·
28 Jan

Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine -- Barrons.com

Dow Jones
·
18 Jan

Moderna's Struggles Could Complicate Bird Flu Fight. What It Means for a Potential Vaccine. -- Barrons.com

Dow Jones
·
14 Jan

BRIEF-Arcturus Therapeutics Initiates Phase 1 H5N1 Flu Vaccine Trial

Reuters
·
10 Jan

Arcturus Therapeutics Holdings Inc - Interim Phase 1 Data Expected H2 2025

THOMSON REUTERS
·
10 Jan

Arcturus Therapeutics Announces Initiation of Phase 1 H5n1 Flu Vaccine Trial

THOMSON REUTERS
·
10 Jan

Arcturus Therapeutics (ARCT) Initiated with a Buy at Piper Sandler

TIPRANKS
·
08 Jan

Vaccine Stocks Surge: Moderna Jumps 11% as COVID-19 and Flu Fears Reignite Immunization Demand

GuruFocus.com
·
08 Jan

Arcturus Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
07 Jan

Arcturus Starts Dosing in Phase 2 Cystic Fibrosis, Ornithine Transcarbamylase Deficiency Treatment Studies

MT Newswires Live
·
07 Jan

BRIEF-Arcturus Therapeutics Announces Initiation Of Dosing In Phase 2 Multiple Ascending Dose Studies For Cystic Fibrosis And Ornithine Transcarbamylase Deficiency

Reuters
·
07 Jan

Arcturus initiates dosing in Phase 2 studies for CF and OTC deficiency

TIPRANKS
·
07 Jan

Arcturus Therapeutics Holdings Inc -Phase 2 Interim Data for Both Mrna Therapeutic Programs on Track for First Half of 2025

THOMSON REUTERS
·
07 Jan

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (Otc) Deficiency

THOMSON REUTERS
·
07 Jan